Applied Proteomics said this week that it has closed a $28 million Series C financing round.
In March 2010, Austin, Texas-based diagnostics firm Vermillion launched sales of its OVA1 ovarian cancer test.
NEW YORK (GenomeWeb News) – Epic Sciences today announced it has completed its Series B financing round raising $13 million.
Protein biomarker diagnostics firm Astute Medical this week said it had completed a Series C financing round that raised $40.4 million.
By Adam Bonislawski
Applied Proteomics announced this week that it has appointed Peter Klemm as CEO and James Blair to its board of directors.
The company said it will use the money, which is an extension of a $26.5 million Series B round completed in May 2010, to advance and expand research, development, and validation of protein biomarker-based laboratory tests.
MBI plans to use the series B venture funding to develop its Apollo sample prep technologies.
CNN reports that researchers have tied a new variant to opioid addiction risk.
Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.
An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.
In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.